InflaRx downgraded by Raymond James with a new price target
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James downgraded InflaRx from Strong Buy to Outperform and set a new price target of $2.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2025 | $2.00 | Strong Buy → Outperform | Raymond James |
| 4/29/2025 | $10.00 | Overweight | Cantor Fitzgerald |
| 4/5/2023 | $8.00 | Neutral → Buy | Guggenheim |
| 2/28/2022 | Buy → Neutral | Guggenheim | |
| 11/8/2021 | $14.00 → $15.00 | Strong Buy | Raymond James |
| 10/28/2021 | $14.00 | Outperform → Strong Buy | Raymond James |
| 8/6/2021 | $11.00 → $10.00 | Outperform | Raymond James |
| 8/6/2021 | $2.80 → $2.50 | Underperform | Credit Suisse |